Newsbenzinga
Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy
· Published
Article summary
Connect Biopharma reports positive Phase 2 results for rademikibart, showing an 81% reduction in COPD treatment failure and high safety.
An excerpt from the original article.
Comments —
Loading comments…